BioCryst Pharmaceuticals Inc (BCRX) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.28x

BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow Reinvestment Rate of 0.28x as of December 2025, reinvesting $77.31 Million (capex $802.00K plus investments $-76.50 Million) from operating cash flow of $276.04 Million. Check BCRX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.28x
(Capex + Investments) / Operating CF

Total Reinvested

$77.31 Million
Capex + Investments

Operating Cash Flow

$276.04 Million
USD

Capital Expenditures

$802.00K
USD

BioCryst Pharmaceuticals Inc Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for BioCryst Pharmaceuticals Inc across 1 annual periods. Explore BCRX long-term investments to assets to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for BioCryst Pharmaceuticals Inc (2025–2025)

Year-by-year capital reinvestment analysis for BioCryst Pharmaceuticals Inc. For live market cap and broader valuation context, see BioCryst Pharmaceuticals Inc market cap and net worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 0.02x $8.06 Million $329.88 Million $2.47 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow